FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999129965> ?p ?o ?g. }

• W2999129965 abstract "Abstract Introduction There were an estimated 21,520 U.S. cases and 10,340 U.S. deaths from all gastric cancer in 2011, with increasing incidence of cancer of the cardia and gastro-esophageal junction. The five year survival of metastatic gastric cancer (mGC) is less than 5%, and long remissions are rare. NCCN guidelines recommend several platinum-based chemotherapy regimens as first line treatment of mGC. Chemotherapy plus trastuzumab is recommended for patients with HER2 positive disease. This study examined treatment patterns, outcomes, and HER2 testing over time in mGC patients treated in community oncology practices. Methods This study was a retrospective review of medical records of patients diagnosed with mGC 1/1/2004 to 7/1/2011, and treated at one of 11 community oncology practices. Patients were≥18 years old, with no concurrent other malignancy. Primary study endpoints were treatment patterns, progression-free survival (PFS), and overall survival (OS). Kaplan-Meier survival analysis and Cox regression were used to examine PFS and OS across regimen groups. Covariates considered for Cox regression models were age, gender, race, stage at initial diagnosis, performance status, liver metastasis, lung metastasis, number of comorbidities, and tumor grade. Results Patients (N=243) were 59.7% Caucasian and 27.2% African American, 60.9% male, with mean age of 63.9 (±13.3) years. Most (70.4%) were initially diagnosed at stage IV; 18.1% had impaired performance status; 28.8%, 20.6%, 10.7% had cancers of gastro-esophageal junction, corpus, and cardia respectively. Of patients alive and under care, by year, HER2 testing had been done on: ≤2005: 0%, 2006: 2.6%, 2007: 3.3%, 2008: 7.5%, 2009: 18.42%, 2010: 41.8%, 2011: 48.1%. Median PFS overall by line was: first line: 4.4 months (N=243); second line: 3.2 months (N=100); third line: 3.0 months (N=38). First line regimen groups, with PFS (in months) by group, were Gp1: docetaxel+platinum±fluoropyrimidine (6.4 months; N=75); Gp2: epirubicin+platinum±fluoropyrimidine (6.7; N=22); Gp3: carboplatin+paclitaxel (3.8; N=21); Gp4: oxaliplatin+fluoropyrimidine (4.4; N=28); Gp5: Other platinum combinations (5.0; N=19); Gp6: Non-platinum regimens (3.7; N=27); Gp7: No systemic therapy (2.1; N=51). Overall log rank test p Conclusion Patients with mGC in community settings have PFS and OS similar to clinical trials. We were not able to detect statistically significant differences in outcomes across treatment regimens due to modest sample size. Treatment patterns reflect increasing testing of HER2 overexpression." @default.
• W2999129965 created "2020-01-23" @default.
• W2999129965 creator A5034752937 @default.
• W2999129965 creator A5040097028 @default.
• W2999129965 creator A5050312301 @default.
• W2999129965 creator A5072015843 @default.
• W2999129965 date "2012-06-01" @default.
• W2999129965 modified "2023-09-27" @default.
• W2999129965 title "P-0056 Treatment Patterns and Outcomes in Metastatic Gastric Cancer in The Community Oncology Setting" @default.
• W2999129965 doi "https://doi.org/10.1016/s0923-7534(20)30263-5" @default.
• W2999129965 hasPublicationYear "2012" @default.
• W2999129965 type Work @default.
• W2999129965 sameAs 2999129965 @default.
• W2999129965 citedByCount "0" @default.
• W2999129965 crossrefType "journal-article" @default.
• W2999129965 hasAuthorship W2999129965A5034752937 @default.
• W2999129965 hasAuthorship W2999129965A5040097028 @default.
• W2999129965 hasAuthorship W2999129965A5050312301 @default.
• W2999129965 hasAuthorship W2999129965A5072015843 @default.
• W2999129965 hasBestOaLocation W29991299651 @default.
• W2999129965 hasConcept C120665830 @default.
• W2999129965 hasConcept C121332964 @default.
• W2999129965 hasConcept C121608353 @default.
• W2999129965 hasConcept C126322002 @default.
• W2999129965 hasConcept C143998085 @default.
• W2999129965 hasConcept C146357865 @default.
• W2999129965 hasConcept C151730666 @default.
• W2999129965 hasConcept C167135981 @default.
• W2999129965 hasConcept C2776694085 @default.
• W2999129965 hasConcept C2776907518 @default.
• W2999129965 hasConcept C2778336483 @default.
• W2999129965 hasConcept C2779013556 @default.
• W2999129965 hasConcept C2779399171 @default.
• W2999129965 hasConcept C2781413609 @default.
• W2999129965 hasConcept C50382708 @default.
• W2999129965 hasConcept C61511704 @default.
• W2999129965 hasConcept C71924100 @default.
• W2999129965 hasConcept C86803240 @default.
• W2999129965 hasConceptScore W2999129965C120665830 @default.
• W2999129965 hasConceptScore W2999129965C121332964 @default.
• W2999129965 hasConceptScore W2999129965C121608353 @default.
• W2999129965 hasConceptScore W2999129965C126322002 @default.
• W2999129965 hasConceptScore W2999129965C143998085 @default.
• W2999129965 hasConceptScore W2999129965C146357865 @default.
• W2999129965 hasConceptScore W2999129965C151730666 @default.
• W2999129965 hasConceptScore W2999129965C167135981 @default.
• W2999129965 hasConceptScore W2999129965C2776694085 @default.
• W2999129965 hasConceptScore W2999129965C2776907518 @default.
• W2999129965 hasConceptScore W2999129965C2778336483 @default.
• W2999129965 hasConceptScore W2999129965C2779013556 @default.
• W2999129965 hasConceptScore W2999129965C2779399171 @default.
• W2999129965 hasConceptScore W2999129965C2781413609 @default.
• W2999129965 hasConceptScore W2999129965C50382708 @default.
• W2999129965 hasConceptScore W2999129965C61511704 @default.
• W2999129965 hasConceptScore W2999129965C71924100 @default.
• W2999129965 hasConceptScore W2999129965C86803240 @default.
• W2999129965 hasLocation W29991299651 @default.
• W2999129965 hasOpenAccess W2999129965 @default.
• W2999129965 hasPrimaryLocation W29991299651 @default.
• W2999129965 isParatext "false" @default.
• W2999129965 isRetracted "false" @default.
• W2999129965 magId "2999129965" @default.
• W2999129965 workType "article" @default.